FDA approves breakthrough pancreatic cancer drug – an oncologist explains how daraxonrasib nearly doubles survival

Pancreatic cancer has historically had an extremely poor prognosis. For patients diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis. This high mortality rate is partly due to the lack of effective screening tests and the fact that the disease rarely causes noticeable symptoms in its early stages. By the time patients experience signs such as jaundice (a yellowing of the skin) or abdominal pain, the cancer has often already spread to other organs. This makes early detection and treatment challenging, contributing to the disease's deadly reputation.

Over 90% of pancreatic tumors are driven by mutations in a gene called KRAS. This gene produces proteins that act as switches controlling cell growth. When mutated, the KRAS gene gets stuck in the 'on' position, causing cancer cells to multiply uncontrollably. For decades, scientists considered KRAS 'undruggable' because its smooth surface lacks the molecular pockets that standard drugs need to bind to and deactivate it. This has made targeting pancreatic cancer particularly difficult, as existing treatments like chemotherapy are less precise and more toxic.

Chemotherapy has been the standard treatment for advanced pancreatic cancer, relying on drugs designed to kill rapidly dividing cells. However, its effectiveness is limited because pancreatic cancer cells often develop resistance to these drugs. Chemotherapy acts like a blunt instrument, causing widespread cell destruction and significant side effects by damaging healthy tissues. This approach has provided only modest improvements in survival, highlighting the urgent need for more targeted therapies.

A breakthrough drug called daraxonrasib was approved by the FDA on August 26, 2026, offering a new way to treat metastatic pancreatic cancer. Unlike previous drugs, daraxonrasib does not bind directly to the KRAS protein. Instead, it attaches to a molecule called cyclophilin A, which helps fold proteins into their final 3D structures. This protein complex then binds to the active KRAS protein, shutting down its ability to signal cancer cells to multiply. The drug is taken daily by mouth and represents a significant advance in precision medicine for pancreatic cancer.

In a Phase 3 clinical trial conducted by Revolution Medicines, 500 patients with metastatic pancreatic cancer who had received prior treatment were studied. The results, presented on May 31, 2026, showed that daraxonrasib nearly doubled overall survival compared to standard chemotherapy. Patients taking daraxonrasib lived an average of 13.2 months after diagnosis, compared to 6.7 months for those on chemotherapy. Additionally, the drug reduced the risk of death for metastatic pancreatic cancer patients by 60%. These findings demonstrate a substantial improvement in survival rates and patient outcomes.

The most common side effect of daraxonrasib is a prominent skin rash, which affected more than 86% of patients in the trial. Other frequent side effects included stomatitis (painful swelling and sores inside the mouth), diarrhea, nausea, and vomiting. Despite these side effects, patients taking daraxonrasib were far less likely to stop treatment due to severe side effects compared to those on chemotherapy. Additionally, patients on daraxonrasib reported an improved quality of life, including reduced pain, making the drug more tolerable for long-term use.